{"id":"fezagepras","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT03081598","NCT02955888","NCT02739217","NCT05349435","NCT03637049","NCT03184584","NCT02538536","NCT04695041","NCT02562573"],"aliases":["PBI-4050"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Fezagepras","companyId":"liminal-biosciences-ltd","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Liminal BioSciences Ltd.","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"Fezagepras","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03081598","phase":"Phase 2","title":"A Phase 2, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PBI-4050 in Type 2 Diabetes Mellitus Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Liminal BioSciences Ltd.","isPivotal":false,"enrollment":104,"indication":"Type 2 Diabetes Mellitus, Metabolic Syndrome","completionDate":"2018-09-06"},{"nctId":"NCT02955888","phase":"Phase 2","title":"A Phase 2, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and Its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients With Abnormal Gluco","status":"TERMINATED","sponsor":"Liminal BioSciences Ltd.","isPivotal":false,"enrollment":11,"indication":"Cystic Fibrosis","completionDate":"2018-02"},{"nctId":"NCT02739217","phase":"Phase 2","title":"A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 and of Its Effects on the Inflammatory, Fibrosis, Diabetes and Obesity Biomarkers in Subjects With Alström S","status":"COMPLETED","sponsor":"Liminal BioSciences Ltd.","isPivotal":false,"enrollment":12,"indication":"Inflammation and Fibrosis, Diabetes","completionDate":"2018-06-04"},{"nctId":"NCT05349435","phase":"Phase 1","title":"A Phase 1, Randomised, Open-Label, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of PBI-4050 Compared to Sodium Phenylbutyrate in Healthy Subjects","status":"TERMINATED","sponsor":"Liminal BioSciences Ltd.","isPivotal":false,"enrollment":8,"indication":"Hyperammonemia","completionDate":"2022-06-30"},{"nctId":"NCT03637049","phase":"Phase 1","title":"A Phase 1, Drug-Drug Interaction Study to Evaluate the Effect of PBI-4050 on the Pharmacokinetics of Midazolam, a Sensitive Cytochrome P450 3A Substrate, in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Liminal BioSciences Ltd.","isPivotal":false,"enrollment":22,"indication":"Healthy","completionDate":"2018-08-22"},{"nctId":"NCT03184584","phase":"Phase 2","title":"An Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome","status":"TERMINATED","sponsor":"Liminal BioSciences Ltd.","isPivotal":true,"enrollment":10,"indication":"Alström Syndrome","completionDate":"2020-05-08"},{"nctId":"NCT02538536","phase":"Phase 2","title":"A Phase 2, Open-label, Single Arm, Exploratory, Observational Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Liminal BioSciences Ltd.","isPivotal":false,"enrollment":41,"indication":"Idiopathic Pulmonary Fibrosis (IPF)","completionDate":"2017-01"},{"nctId":"NCT04695041","phase":"Phase 1","title":"A Phase 1, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of PBI-4050 in Healthy Subjects","status":"COMPLETED","sponsor":"Liminal BioSciences Ltd.","isPivotal":false,"enrollment":65,"indication":"Fibrosis, Inflammation","completionDate":"2021-10-05"},{"nctId":"NCT02562573","phase":"Phase 2","title":"A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome","status":"COMPLETED","sponsor":"Liminal BioSciences Ltd.","isPivotal":false,"enrollment":24,"indication":"Type 2 Diabetes, Metabolic Syndrome","completionDate":"2016-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}